Physician profile
William Curtis
NPI 1578541702
$1,033.64
in general payments reported to CMS, 2019-2025
15 companies · $24.23 in 2025
The $24.23 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.97 · 2020: $146 · 2021: $132 · 2022: $244 · 2023: $285 · 2024: $135 · 2025: $24.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $241.52 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $186.14 | 2023-2024 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $157.77 | 2020-2024 | Ozempic |
| Glaxosmithkline, LLC. | $103.23 | 2022-2024 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $80.26 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $50.32 | 2019-2022 | |
| Amgen INC. | $45.33 | 2022-2023 | Otezla, Repatha |
| Astellas Pharma US INC | $32.78 | 2019-2023 | Myrbetriq |
| Csl Behring | $24.23 | 2025 | Haegarda |
| Genentech USA, INC. | $21.40 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.59 | 2023 | Jardiance, Tradjenta |
| Almatica Pharma LLC | $20.58 | 2021 | |
| Exact Sciences Corporation | $17.66 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.90 | 2022 | |
| Pfizer INC. | $14.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.